Recent News

• 06.10.2025 - Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
• 05.22.2025 - Unicycive Therapeutics to Present at Upcoming Investor Conferences
• 05.21.2025 - Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
• 05.14.2025 - Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 06.10.2025 - EX-99.1 EX-99.1
• 06.10.2025 - 8-K Current report
• 06.09.2025 - 8-K Current report
• 06.09.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.22.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.21.2025 - EX-99.1 EX-99.1
• 05.21.2025 - 8-K Current report
• 05.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors